Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics Revenues Increase, Losses Narrow Slightly in Q2 of 2004

NEW YORK, Jan. 28 (GenomeWeb News) - Celera Diagnostics reported increased revenues and slightly smaller losses for the fiscal year 2004 second quarter today, along with decreased R&D spending.


For the quarter ended Dec. 31, 2003, Celera Diagnostics, a joint venture of Applied
Biosystems and Celera Genomics, both units of Applera, reported revenues of $11 million, compared to $7.8 million for the same period a year ago.


The company's net loss for the quarter amounted to $9.3 million, compared to $9.9 million in the prior year quarter.


Celera Diagnostics spent $10.6 million for R&D and engineering during the quarter, compared to $12.6 million the year before.



The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.